Dr. McCool has 20 years of practice in the biotech field and has held various management and technical positions at Lonza Pharma & Biotech and Mascoma Corp., a subsidiary of Lallemand. He joined the site leadership team of Cytovance in 2013 to help position the company for growth and acquisition. Prior to his appointment as chief executive, Dr. McCool served as the chief technology officer.
“Jesse has been a driving force of the senior leadership team and has been critical to the business transformation strategy,” said Dr. Wang. “His depth of knowledge of our industry, professional reputation and professional network have helped to propel Cytovance into a leading CDMO that is well recognized for responsiveness, reliability and resourcefulness. In his role as CTO, Jesse was focused on fleshing out the strategy and aligning it with the strategic intent of our parent company. As CEO, he will propel the company even further.”